{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:43:42Z","timestamp":1780710222959,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejpb.2023.10.001","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T06:30:09Z","timestamp":1696833009000},"page":"161-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Challenges in the transfer and scale-up of mini-tableting: Case study with losartan potassium"],"prefix":"10.1016","volume":"192","author":[{"given":"Valentin\u00eb","family":"Lura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klinken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Breitkreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.10.001_b0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4038\/cmj.v61i3.8340","article-title":"Time to change the paradigm of children's medicines from liquid formulations to flexible solid oral dosage forms","volume":"61","author":"Hoppu","year":"2016","journal-title":"Ceylon Med. J."},{"key":"10.1016\/j.ejpb.2023.10.001_b0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.xphs.2018.11.013","article-title":"Pediatric oral formulations: an updated review of commercially available pediatric oral formulations since 2007","volume":"108","author":"Strickley","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.10.001_b0015","unstructured":"World Health Organization (WHO), Report of the informal expert meeting on dosage forms of medicines for children, 2008."},{"key":"10.1016\/j.ejpb.2023.10.001_b0020","unstructured":"European Parliament and Council, Regulation EC 1901\/2006 (12 December 2006) on medicinal products for paediatric use and amending Regulation EEC 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation EC 726\/2004, 2006."},{"key":"10.1016\/j.ejpb.2023.10.001_b0025","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.clinthera.2008.11.016","article-title":"European perspectives on pediatric formulations","volume":"30","author":"Breitkreutz","year":"2008","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2023.10.001_b0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5173(98)00206-3","article-title":"Minitabletting: improving the compactability of paracetamol powder mixtures","volume":"173","author":"Lennartz","year":"1998","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0035","article-title":"Tableting of mini-tablets in comparison with conventionally sized tablets: a comparison of tableting properties and tablet dimensions","volume":"2","author":"Lura","year":"2020","journal-title":"Int. J. Pharm.: X"},{"key":"10.1016\/j.ejpb.2023.10.001_b0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpeds.2018.05.031","article-title":"Acceptability of multiple uncoated minitablets in infants and toddlers: a randomized controlled trial","volume":"201","author":"Klingmann","year":"2018","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpb.2023.10.001_b0045","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jpeds.2015.07.010","article-title":"Acceptability of uncoated mini-tablets in neonates - a randomized controlled trial","volume":"167","author":"Klingmann","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpb.2023.10.001_b0050","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jpeds.2013.07.014","article-title":"Favorable acceptance of mini-tablets compared with syrup: a randomized controlled trial in infants and preschool children","volume":"163","author":"Klingmann","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejpb.2023.10.001_b0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/archdischild-2011-300958","article-title":"Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study","volume":"97","author":"Spomer","year":"2012","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejpb.2023.10.001_b0060","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/idoj.IDOJ_287_18","article-title":"Newer treatment modalities in Epidermolysis Bullosa","volume":"10","author":"Bruckner-Tuderman","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.ejpb.2023.10.001_b0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40291-020-00466-7","article-title":"Molecular therapeutics in development for Epidermolysis Bullosa: update 2020","volume":"24","author":"Has","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ejpb.2023.10.001_b0070","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.14974.1","article-title":"Recent advances in understanding and managing epidermolysis bullosa","volume":"7","author":"Kiritsi","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.ejpb.2023.10.001_b0075","unstructured":"D. Kiritsi, B. Stiller, K.A. Nystroem, L.K. Bruckner-Tuderman, Use of losartan for the treatment of fibrotic diseases, in particular Epidermolysis Bullosa, EP 3 842 099 A1 (2021)."},{"key":"10.1016\/j.ejpb.2023.10.001_b0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.matbio.2018.01.016","article-title":"Injury- and inflammation-driven skin fibrosis: the paradigm of Epidermolysis Bullosa","volume":"68\u201369","author":"Nystr\u00f6m","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0085","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan ameliorates dystrophic Epidermolysis Bullosa and uncovers new disease mechanisms","volume":"7","author":"Nystr\u00f6m","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejpb.2023.10.001_b0090","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jid.2015.10.050","article-title":"Progress toward treatment and cure of Epidermolysis Bullosa: summary of the DEBRA International Research Symposium EB2015","volume":"136","author":"Uitto","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0095","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jid.2017.12.016","article-title":"EB2017 - Progress in Epidermolysis Bullosa research toward treatment and cure","volume":"138","author":"Uitto","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.matbio.2016.07.009","article-title":"Molecular pathology of the basement membrane zone in heritable blistering diseases: the paradigm of Epidermolysis Bullosa","volume":"57\u201358","author":"Uitto","year":"2017","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0105","author":"European Pharmacopoeia","year":"2020"},{"key":"10.1016\/j.ejpb.2023.10.001_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030570","article-title":"Pharmaceutical development of film-coated mini-tablets with losartan potassium for Epidermolysis Bullosa","volume":"14","author":"Elezaj","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.10.001_b0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3109\/03639048909058530","article-title":"Use of a compaction simulator system in tabletting research","volume":"15","author":"\u00c7elik","year":"1989","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jps.20262","article-title":"Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction","volume":"94","author":"Tye","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.10.001_b0125","article-title":"Screening of lubricants towards their applicability for external lubrication","volume":"632","author":"de Backere","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.powtec.2015.04.004","article-title":"Dependence of ejection force on tableting speed - a compaction simulation study","volume":"279","author":"Sun","year":"2015","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118468","article-title":"Influence of the unloading conditions on capping and lamination: study on a compaction simulator","volume":"567","author":"Mazel","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0140","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/jps.22032","article-title":"Evaluation of a rotary tablet press simulator as a tool for the characterization of compaction properties of pharmaceutical products","volume":"99","author":"Michaut","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.10.001_b0145","article-title":"Compressibility analysis as robust in-die compression analysis for describing tableting behaviour","volume":"1","author":"Berkenkemper","year":"2022","journal-title":"RPS Pharm. Pharmacol. Rep."},{"key":"10.1016\/j.ejpb.2023.10.001_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12040310","article-title":"Scaling tableting processes from compaction simulator to rotary presses - mind the sub-processes","volume":"12","author":"W\u00fcnsch","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.10.001_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120636","article-title":"Transfer and scale-up of the manufacturing of orodispersible mini-tablets from a compaction simulator to an industrial rotary tablet press","volume":"602","author":"Lura","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122616","article-title":"Upscaling of external lubrication from a compaction simulator to a rotary tablet press","volume":"633","author":"de Backere","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121562","article-title":"Effect of feed frame on lubricant sensitivity during upscaling from a compaction simulator to a rotary tablet press","volume":"616","author":"de Backere","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0170","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.powtec.2013.10.007","article-title":"Compression prediction accuracy from small scale compaction studies to production presses","volume":"270","author":"Pitt","year":"2015","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.powtec.2018.02.052","article-title":"Hybrid modeling of roll compaction processes with the Styl'One Evolution","volume":"341","author":"Reimer","year":"2019","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijpharm.2003.09.034","article-title":"Simulation of roller compaction using a laboratory scale compaction simulator","volume":"269","author":"Zinchuk","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118810","article-title":"Elastic recovery in roll compaction simulation","volume":"573","author":"Keizer","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0190","unstructured":"Food and Drug Administration, Guidance for industry: Immediate release solid oral dosage forms: Scale-up and postapproval changes: Chemistry manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1995."},{"key":"10.1016\/j.ejpb.2023.10.001_b0195","unstructured":"European Medical Agency, Guideline on process validation for finished products - information and data to be provided in regulatory submissions, EMA\/CHMP\/CVMP\/QWP\/749073\/2016, 2016."},{"key":"10.1016\/j.ejpb.2023.10.001_b0200","unstructured":"European Pharmacopoeia, Ph. Eur. 2.9.34 Bulk Density and Tapped Density of Powders, 10th ed., Deutscher Apotheker Verlag, Stuttgart, Germany, 2020."},{"key":"10.1016\/j.ejpb.2023.10.001_b0205","unstructured":"European Pharmacopoeia, Ph. Eur. 2.9.36 Powder flow, 10th ed., Deutscher Apotheker Verlag, Stuttgart, Germany, 2020."},{"key":"10.1016\/j.ejpb.2023.10.001_b0210","unstructured":"European Pharmacopoeia, Ph. Eur. 2.9.5 Uniformity of mass of single-dose preparations, 10th ed., Deutscher Apotheker Verlag, Stuttgart, Germany, 2020."},{"key":"10.1016\/j.ejpb.2023.10.001_b0215","unstructured":"European Pharmacopoeia, Ph. Eur. 2.9.40 Uniformity of dosage units, 10th ed., Deutscher Apotheker Verlag, Stuttgart, Germany, 2020."},{"key":"10.1016\/j.ejpb.2023.10.001_b0220","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jps.2600590523","article-title":"Determination of tablet strength by the diametral-compression test","volume":"59","author":"Fell","year":"1970","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.10.001_b0225","unstructured":"P. Kleinebudde, Pharmazeutische Pellets durch Extrudieren\/Sph\u00e4ronisieren: Herstellung, Eigenschaften, Modifizierung, Habilitation thesis, Kiel, Germany, 1997."},{"key":"10.1016\/j.ejpb.2023.10.001_b0230","unstructured":"European Pharmacopoeia, Ph. Eur. 2.9.1 Disintegration of tablets and capsules, 10th ed., Deutscher Apotheker Verlag, Stuttgart, Germany, 2020."},{"key":"10.1016\/j.ejpb.2023.10.001_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111909","article-title":"Blend segregation in tablets manufacturing and its effect on drug content uniformity - a review","volume":"13","author":"Jakubowska","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2023.10.001_b0240","doi-asserted-by":"crossref","first-page":"28P","DOI":"10.1111\/j.2042-7158.1985.tb14100.x","article-title":"The effect of machine speed on the compaction of some directly compressible tablet diluents","volume":"37","author":"Armstrong","year":"1985","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0245","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1080\/03639045.2016.1200067","article-title":"Lubricant sensitivity in function of paddle movement in the forced feeder of a high-speed tablet press","volume":"42","author":"Peeters","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0250","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10837450.2014.954728","article-title":"A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms","volume":"20","author":"Leane","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0255","first-page":"763","article-title":"A critical review on tablet disintegration","volume":"21","author":"Quodbach","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2023.10.001_b0260","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijpharm.2017.04.037","article-title":"Feasibility of mini-tablets as a flexible drug delivery tool","volume":"525","author":"Mitra","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.10.001_b0265","series-title":"Pharmaceutical powder compaction technology: Chapter 9 Lubrication issues in direct compaction","year":"2011"},{"key":"10.1016\/j.ejpb.2023.10.001_b0270","unstructured":"European Pharmacopoeia, Ph. Eur. Tablets, 10th ed., Deutscher Apotheker Verlag, Stuttgart, Germany, 2020."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123002618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:32Z","timestamp":1760547272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123002618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":54,"alternative-id":["S0939641123002618"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.10.001","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in the transfer and scale-up of mini-tableting: Case study with losartan potassium","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}